A pharma giant wants to lobby the province on legislative and regulatory issues related to the life sciences sector.
GlaxoSmithKline Inc. was registered in-house this past week with the Office of the Integrity Commissioner of Ontario by Sridhar Venkatesh, the company's general manager.
According to its filing, the company wants to have meaningful input regarding legislative or regulatory proposals related to pharmaceutical drug policy (including vaccines) in Ontario that may have an impact on the company, and/or the growth and sustainability of the life sciences industry in Ontario, health system sustainability and transparency, and/or or patients' access to innovative medications in Ontario. This includes providing input and recommendations regarding Bill 160, the Strengthening Quality and Accountability for Patients Act, 2017 (namely the Health Sector Payment Transparency Act), and future regulations under that Act, so that patients can make better informed decisions regarding their health care.